ABEO

Abeona Therapeutics Stock Analysis

AI Rating

Good
  • Quality2/10
  • Growth 9/10
  • Value 4/10
Abeona Therapeutics sales and earnings growth
ABEO Growth
Great
  • Revenue Y/Y 0.00%
  • EPS Y/Y 252.44%
  • FCF Y/Y -35.33%
Abeona Therapeutics gross and profit margin trends
ABEO Profitability
Great
  • Gross margin 70.90%
  • EPS margin 454.90%
  • ROIC 5Y -33.67%
Abeona Therapeutics net debt vs free cash flow
ABEO Risk
Great
  • Debt / Equity 0.2
  • Debt / FCF 0.0
  • Interest coverage 19.5

Abeona Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks